Tafamidis trial: analysts say early signals point to Pfizer (PFE) win - upside for BridgeBio (BBIO), downside for generics manufacturers
Analysts are looking ahead to the tafamidis patent trial involving Pfizer (NYSE: PFE), as recent court developments begin to shape investor expectations ahead of the proceedings next week.
Current commentary suggests there might be early signs of a Pfizer victory emerging from pre-trial developments, including the narrowing of the case by taking two patents off the table on April 21st.
A partial consent judgment, agreed to by the parties saw, Dexcel, a generics manufacturer, drop its challenges to the validity and enforceability of U.S. Patent Nos. 7,214,695 and 7,214,696. The court granted judgment in favor of Pfizer on the claims stemming from those patents.
This narrowing of the case, alongside Pfizer’s assertion of broad claims of infringement under the ‘441 patent, have been interpreted favorably as bullish signals for a Pfizer victory by some analysts.
Pfizer’s (PFE) case
Pfizer is taking legal action against three generic drug manufacturers, including Dexcel Pharma Technologies, Cipla Ltd (CIPLA) and Hikma Pharmaceuticals PLC (HIK) on grounds that they are infringing upon Pfizer’s Vyndamax patent. In response, the defendants challenge the patent’s validity.
The case, set to be heard in the United States District Court for the District of Delaware from April 27th, is the culmination of a more than two-and-a-half-year legal dispute between Pfizer and the generic manufacturers. Market analysts are watching closely to see whether Pfizer will prevail or if generic medications will enter the market earlier than anticipated.
At the center of the issue is the durability of Vyndamax's patent 9,770,441 (“the ‘441 patent”), which extends to August 2035 and represents the upper bound for potential generic entry. Earlier patents expiring in December 2028 are no longer in dispute. This has led to a wide range of investor speculation around the timing of Pfizer’s loss of exclusivity.
Impact: share prices
Equity analysts at Mizuho recently noted that investors have, in general, taken a more conservative stance, modelling that Pfizer’s patent protection will only last until year-end 2028. That said, Mizuho believes that Pfizer has a “better-than-Street probability” of winning on the 2035 patent or obtaining a highly favorable settlement result.
However, the trial outcome remains uncertain, and these early signals from the courthouse are not conclusive. News flow during the trial may offer directional short-term read-through for positioning, but it may be difficult to translate day-to-day developments into clear trades.
The five-day bench trial is scheduled to run until May 1st, unless a settlement is reached beforehand. A final ruling is unlikely to be immediate, with judgment typically delivered weeks or months after proceedings conclude.
BridgeBio (BBIO) read-through
The dynamic has implications across the ATTR-CM landscape, including for BridgeBio Pharma (NASDAQ: BBIO), where the case centers on the durability of its Attruby franchise. BridgeBio currently trades at around $73.90.
Mizuho highlighted that a favorable outcome for Pfizer would benefit BridgeBio and could represent the single largest potential driver for its stock this year. In its view, an outright win could put BridgeBio stock in the $100-110 range or higher.
For now, analysts frame the latest developments as a very early indication from the courthouse that Pfizer will maintain its patent exclusivity. This is far from decisive, but it is seen as a positive sign for those holding more bullish positions. Ultimately, upside scenarios may gain growing support relative to more conservative expectations. Pharma Wire will report on developments as they break.